Physician profile
Thomas E Dougherty
NPI 1245256502
$5,089.96
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,397 · 2020: $1,199 · 2021: $2,494.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $736.54 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $707.76 | 2019-2021 | |
| Pfizer INC. | $629.93 | 2019-2021 | |
| Novo Nordisk INC | $428.97 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $419.09 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $374.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $371.07 | 2019-2021 | |
| Esperion Therapeutics, INC. | $310.81 | 2020-2021 | |
| Amgen INC. | $207.95 | 2019-2021 | |
| Gilead Sciences, INC. | $200.00 | 2021 | |
| Lilly USA, LLC | $193.22 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $113.35 | 2019 | |
| Abbvie INC. | $80.03 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $68.43 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $57.75 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $47.75 | 2019-2021 | |
| Mylan Specialty L.P. | $45.23 | 2019-2020 | |
| Amarin Pharma, INC. | $34.87 | 2019 | |
| Nestle Healthcare Nutrition INC. | $22.50 | 2021 | |
| Allergan, INC. | $21.74 | 2019 | |
| Astellas Pharma US INC | $18.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dougherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.